CRISPR-Cas9 is a powerful gene editing system that has revolutionized our ability to treat disease and probe the human genome ...

The CRISPR-Cas9 patent landscape remains complex and unsettled. The Federal Circuit’s latest decision in University of California v.

The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell ...

For years, the CRISPR-Cas9 genome technology has been reshaping ... “The ability to apply CRISPR gene-editing to spider silk is very promising for materials science research – for example ...

Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).

The gene editor -- called evoCAST -- goes a long way toward solving a problem that has confounded the development of gene therapies from the field's beginnings: How to add long stretches of DNA to ...

Gene editing, once a theoretical ambition, has matured into a revolutionary frontier in biotechnology. Technologies like CRISPR-Cas9, TALENs, and Zinc Finger Nucleases (ZFNs) have unlocked ...

This is the first gene editor to use a CRISPR-associated transposase to make targeted edits at therapeutically useful levels ...

Mobile genetic elements such as CAST provide an idea of the coding potential of nature for genome manipulation. It is in the ...